Machine Learning of Multi-Modal Tumor Imaging Reveals Trajectories of Response to Precision Treatment.

Simple Summary: In order to evaluate precision cancer therapies, it would be advantageous to measure at the same time their action on tumor growth and on the biological target of the therapy. New non-invasive hybrid imaging techniques allow access to multiple quantitative parameters. Here, we trained machine learning classifiers of features extracted from longitudinal in vivo co-registered metabolic, vascular and anatomical images in a mouse model of paraganglioma. We show that machine learning identifies ensembles of tumor states that correspond to stages of tumor evolution with or without anti-angiogenic treatment. These classifiers define individual trajectories of tumor progression and response to treatment, supporting the use of machine learning analysis of multiparametric imaging for the identification of response to anti-angiogenic treatment in this rodent model. The standard assessment of response to cancer treatments is based on gross tumor characteristics, such as tumor size or glycolysis, which provide very indirect information about the effect of precision treatments on the pharmacological targets of tumors. Several advanced imaging modalities allow for the visualization of targeted tumor hallmarks. Descriptors extracted from these images can help establishing new classifications of precision treatment response. We propose a machine learning (ML) framework to analyze metabolic–anatomical–vascular imaging features from positron emission tomography, ultrafast Doppler, and computed tomography in a mouse model of paraganglioma undergoing anti-angiogenic treatment with sunitinib. Imaging features from the follow-up of sunitinib-treated (n = 8, imaged once-per-week/6-weeks) and sham-treated (n = 8, imaged once-per-week/3-weeks) mice groups were dimensionally reduced and analyzed with hierarchical clustering Analysis (HCA). The classes extracted from HCA were used with 10 ML classifiers to find a generalized tumor stage prediction model, which was validated with an independent dataset of sunitinib-treated mice. HCA provided three stages of treatment response that were validated using the best-performing ML classifier. The Gaussian naive Bayes classifier showed the best performance, with a training accuracy of 98.7 and an average area under curve of 100. Our results show that metabolic–anatomical–vascular markers allow defining treatment response trajectories that reflect the efficacy of an anti-angiogenic drug on the tumor target hallmark. [ABSTRACT FROM AUTHOR]